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Gene therapy: Repairing haemoglobin disorders with ribozymes
D.J. Weatherall
A ribozyme-mediated approach has made it possible to
replace the region in b globin mRNA containing the
sickle-cell-anaemia mutation with a g-globin-encoding
sequence. This is an interesting new way of correcting
monogenic disease, but there are major problems to
overcome before it could be applied in the clinic.
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The inherited disorders of haemoglobin, particularly the
thalassaemias and sickle cell anaemia, are the commonest
monogenic diseases and are likely to pose an increasingly
serious public health problem for many countries in the
new millennium [1]. Control of these disorders by prenatal
diagnosis is not acceptable to some countries, and
although they can be cured by bone-marrow transplanta-
tion, this is possible only if there is a matching donor avail-
able. Symptomatic treatment is expensive and not entirely
satisfactory. Hence, particularly as their molecular pathol-
ogy is so well understood, there has been great interest in
exploring more definitive ways of treating these disorders
by genetic manipulation.
The development of gene therapy for the haemoglobin
disorders poses formidable problems [2]. Human adult
haemoglobin, haemoglobin A, is made up of two pairs of
globin-chain subunits, α and β, which must be synthesised
in approximately equal amounts; any imbalance of globin-
chain production leads to a thalassaemic phenotype. Fur-
thermore, a high level of gene expression, producing
somewhere in the region of 15 picograms of haemoglobin
per red blood cell, is required. And although much is
known about the regulation of the α and β globin gene
clusters, it is still not absolutely clear whether all the
sequences have been identified that are required for
tightly regulated, high level expression over a long period. 
There has been considerable success in obtaining high-
level human globin gene expression in transgenic animals
[3,4], but despite a great deal of work this has not been
achieved using any of the currently available vectors for
gene transfer. To obtain a useful clinical result, it would
be necessary to transfect a relatively large stem-cell
population. Here, again, it has been very difficult to
develop gene-transfer systems of the appropriate
efficiency. And although there have been successes in
correcting the β globin disorders in vitro by site-directed
recombination, the level of efficiency is so low as to render
this impractical, at least with current technology [5].
There is, however, a completely different approach to the
control of the β globin disorders [6,7]. In fetal life, the
major haemoglobin is haemoglobin F, which has two α
chains and two γ chains (α2γ2). Over the first few months
after birth, γ chains are replaced by β chains, reflecting a
switch from haemoglobin F to haemoglobin A production.
It has been known for a long time that those patients with β
thalassaemia or sickle cell anaemia who synthesise a rela-
tively large amount of haemoglobin F after the neonatal
period have a milder clinical disorder. In the case of sickle
cell anaemia, haemoglobin F interferes with the polymeri-
sation of sickle haemoglobin and hence reduces the rate of
intravascular sickling. In β thalassaemia, augmented γ chain
Figure 1
Ribozyme-mediated repair of sickle β globin transcripts in human
erythrocyte precursors. The figure outlines the scheme for converting
βS globin messenger RNAs into transcripts encoding γ globin, as
reported recently by Lan et al. [10].
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production reduces the overall level of globin chain imbal-
ance caused by defective β chain synthesis. The ameliorat-
ing effects of unusually high levels of fetal haemoglobin on
these diseases have been highlighted by a series of ‘experi-
ments of nature’, in which it has been observed that
patients who also inherit genes that result in high levels of γ
chain synthesis in adult life have a much milder illness
[7,8]. The encouraging results of efforts directed at the
pharmacological manipulation of fetal haemoglobin in the
haemoglobin disorders are reviewed elsewhere [9].
Lan et al. [10] have recently described a novel approach
to the correction of the molecular defect that underlies
sickle cell anaemia, which combines the double benefit
of deleting the sickle-cell (βS) mutation and, potentially,
augmenting fetal haemoglobin levels in the red cells.
Their ingenious experiment exploited the catalytic prop-
erties of ribozymes to alter the defective mRNA pro-
duced by the mutant β haemoglobin gene, and is
outlined in Figure 1. First, a source of nucleated red cell
precursors was obtained by growing erythroid colonies
from the peripheral blood of patients with sickle cell
anaemia. A trans-splicing group 1 ribozyme was then
used to alter the mutant β globin transcripts in these
cells. In short, Lan et al. [10] created a trans-splicing
ribozyme that was able to convert the βS globin tran-
scripts into RNAs encoding γ globin. Remarkably,
sequence analysis of eight different cDNA subclones
derived from blood cells that were taken from sickle cell
anaemia patients and treated in this way demonstrated
that, in each case, the ribozyme had correctly spliced its γ
globin 3′ exon onto nucleotide 61 of the β globin target
transcript and, in the process, had maintained an open
reading frame for translation of the mRNA. These exper-
iments suggest that trans-splicing ribozymes are able to
correct mutant globin transcripts in primary human red
cell precursors at a high level of fidelity.
As Lan et al. [10] point out, RNA repair of this type
could be particularly appropriate for the treatment of
sickle cell disease, because not only is the sickle muta-
tion removed by the ribozyme but, at the same time, the
globin chain that is encoded by the hybrid RNA product
has the anti-sickling properties of the γ chains of fetal
haemoglobin. Lan et al. also suggest that it may not be
necessary to repair 100% of the transcripts; patients with
sickle cell disease that express γ globin at 10–20% of the
βS globin level in most of their red cells tend to have a
milder disease. 
This approach has other potential advantages. In adult
life, haemoglobin F production is uneven between differ-
ent red-cell precursors (Figure 2). Because haemoglobin F
interferes with sickling, those red cells that produce rela-
tively more fetal haemoglobin undergo intense selection
in the circulation of patients with sickle-cell anaemia, and
have a longer survival [6,7]. A population of precursors
treated in this way would thus be expected to expand in
the blood, simply by selective amplification. 
Although these results are very encouraging, there are
formidable problems to be overcome before the fruits of
the elegant experiment carried out by Lan et al. [10] can
be applied in clinical practice. First, it is not clear how it
would be possible to scale up the operation such that a
sufficient number of red-cell precursors could be treated
in vivo to obtain a useful clinical effect. And as this form of
therapy is directed at transcription products, rather than
the defective gene itself, how often would it have to be
repeated to provide effective long-term therapy?
There is another problem which is not just confined to this
particular approach, but which is relevant to any form of
gene therapy for sickle cell anaemia. It has been believed
for a long time, both from the results of in vitro viscosity
studies and from clinical observations, that to control sick-
ling, either in vitro in artificial mixtures of sickle cells and
normal cells or in patients, it is necessary to reduce the
sickle cell population to somewhere below 30% of the
total; above this level there is a rapid increase in blood vis-
cosity on deoxygenation [11]. Thus, at least theoretically,
there is a danger in adding a normal — that is non-sickling
— population of red cells to the blood of a patient with
sickle cell anaemia unless it constitutes more than about
70% of the total cell population. At any lower frequency,
the non-sickling cells may increase blood viscosity without
sufficiently reducing the overall numbers of sickling cells,
and hence exacerbate the disorder. 
Figure 2
The distribution of haemoglobins F and S in the blood of a patient with
sickle cell anaemia. This preparation was treated with a fluorescent
antibody that labels γ globin chains. The unequal distribution of
haemoglobin F among the red cell population is clearly shown, and in
the centre of the field there is an irreversibly sickled cell which contains
no detectable fetal haemoglobin.
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Indeed, this last concern has formed the basis for current
policies regarding blood transfusion in sickle cell anaemia.
Patients with serious complications are treated by
exchange transfusion to reduce the proportion of sickle-
able cells to below 30% of the red cell population, and
conventional transfusion is given only if the haemoglobin
level is unusually low. If long-term transfusion is
embarked on, it is designed to suppress endogenous red
cell production to maintain a low level of sickle cells in the
blood. These policies may have to be revised as the result
of more recent clinical trials suggesting that it may be safe
to transfuse children with this disease to a haemoglobin
level of about 10 grams per decilitre [12] with normal red
cells. However, even patients who have unusually high
haemoglobin and haemoglobin F levels and are protected
against some features of sickle cell anaemia, like those of
Eastern Saudi Arabia, still have bone disease and other
severe complications [13].
There is, therefore, a potential danger in any form of gene
therapy that might produce a population of non-sickleable
cells in the blood of a patient with sickle cell anaemia.
Until more is known about the relationship between the
haemoglobin S and haemoglobin F levels and the clinical
course, and the effects of maintaining higher haemoglobin
levels by transfusion without reducing the numbers of
sickle cells to the levels that have hitherto been
advocated, it will not be possible to predict the effects of
correcting the sickling defect in a limited sub-population
of red cells. Despite these concerns, however, this new
approach to the correction of monogenic disease through
ribozyme-mediated repair is an interesting addition to the
gene therapy armamentarium, and one which should cer-
tainly be explored further.
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